For the three pathological entities studied (GHD, SGA and PWS), we found that the determination of IGF1/IGFBP3 molar ratio was a useful additional tool for the adaptation of rGH treatment with a view to improving safety. Here, IGFBP3 is linked to Prader-Willi syndrome.